|
1
|
Νeagu M: The immune system: A hidden
treasure for biomarker discovery in cutaneous melanoma. Adv Clin
Chem. 58:89–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boda D, Docea AO, Calina D, Ilie MA,
Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE,
Voiculescu V, et al: Human papilloma virus: Apprehending the link
with carcinogenesis and unveiling new research avenues (Review).
Int J Oncol. 52:637–655. 2018.PubMed/NCBI
|
|
3
|
Calleja-Agius J, Brincat M and Borg M:
Skin connective tissue and ageing. Best Pract Res Clin Obstet
Gynaecol. 27:727–740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fisher GJ, Kang S, Varani J, Bata-Csorgo
Z, Wan Y, Datta S and Voorhees JJ: Mechanisms of photoaging and
chronological skin aging. Arch Dermatol. 138:1462–1470. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martinon F, Burns K and Tschopp J: The
inflammasome: A molecular platform triggering activation of
inflammatory caspases and processing of proIL-β. Mol Cell.
10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sollberger G, Strittmatter GE, Grossi S,
Garstkiewicz M, Auf dem Keller U, French LE and Beer HD: Caspase-1
activity is required for UVB-induced apoptosis of human
keratinocytes. J Invest Dermatol. 135:1395–1404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ortiz ML, Kumar V, Martner A, Mony S,
Donthireddy L, Condamine T, Seykora J, Knight SC, Malietzis G, Lee
GH, et al: Immature myeloid cells directly contribute to skin tumor
development by recruiting IL-17-producing CD4+ T cells.
J Exp Med. 212:351–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Awad F, Assrawi E, Louvrier C, Jumeau C,
Giurgea I, Amselem S and Karabina SA: Photoaging and skin cancer:
Is the inflammasome the missing link? Mech Ageing Dev. 172:131–137.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DeNardo DG and Coussens LM: Inflammation
and breast cancer. Balancing immune response: Crosstalk between
adaptive and innate immune cells during breast cancer progression.
Breast Cancer Res. 9:2122007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neagu M, Constantin C, Dumitrascu G, Lupu
A, Caruntu C, Boda D and Zurac S: Inflammation markers in cutaneous
melanoma-edgy biomarkers for prognosis. Discoveries (Craiova).
3:e382015. View Article : Google Scholar
|
|
12
|
Lin WW and Karin M: A cytokine-mediated
link between innate immunity, inflammation, and cancer. J Clin
Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neagu M, Constantin C, Manda G and
Margaritescu I: Biomarkers of metastatic melanoma. Biomarkers Med.
3:71–89. 2009. View Article : Google Scholar
|
|
14
|
Mattii M, Lovászi M, Garzorz N, Atenhan A,
Quaranta M, Lauffer F, Konstantinow A, Küpper M, Zouboulis CC,
Kemeny L, et al: Sebocytes contribute to skin inflammation by
promoting the differentiation of T helper 17 cells. Br J Dermatol.
178:722–730. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neagu M, Caruntu C, Constantin C, Boda D,
Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin
carcinogenesis: Updates in experimental models (Review). Oncol Rep.
35:2516–2528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martinon F: Dangerous liaisons:
Mitochondrial DNA meets the NLRP3 inflammasome. Immunity.
36:313–315. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feldmeyer L, Keller M, Niklaus G, Hohl D,
Werner S and Beer HD: The inflammasome mediates UVB-induced
activation and secretion of interleukin-1beta by keratinocytes.
Curr Biol. 17:1140–1145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Broz P and Dixit VM: Inflammasomes:
Mechanism of assembly, regulation and signalling. Nat Rev Immunol.
16:407–420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kostyuk V, Potapovich A, Stancato A, De
Luca C, Lulli D, Pastore S and Korkina L: Photo-oxidation products
of skin surface squalene mediate metabolic and inflammatory
responses to solar UV in human keratinocytes. PLoS One.
7:e444722012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oyewole AO and Birch-Machin MA: Sebum,
inflammasomes and the skin: Current concepts and future
perspective. Exp Dermatol. 24:651–654. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahmad I, Muneer KM, Chang ME, Nasr HM,
Clay JM, Huang CC and Yusuf N: Ultraviolet radiation-induced
downregulation of SERCA2 mediates activation of NLRP3 inflammasome
in basal cell carcinoma. Photochem Photobiol. 93:1025–1033. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Latz E, Xiao TS and Stutz A: Activation
and regulation of the inflammasomes. Nat Rev Immunol. 13:397–411.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Penuela S, Gyenis L, Ablack A, Churko JM,
Berger AC, Litchfield DW, Lewis JD and Laird DW: Loss of pannexin 1
attenuates melanoma progression by reversion to a melanocytic
phenotype. J Biol Chem. 287:29184–29193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhong FL, Mamaï O, Sborgi L, Boussofara L,
Hopkins R, Robinson K, Szeverényi I, Takeichi T, Balaji R, Lau A,
et al: Germline NLRP1 mutations cause skin inflammatory and
cancersusceptibility syndromes via inflammasome activation. Cell.
167:187–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Verma D, Bivik C, Farahani E, Synnerstad
I, Fredrikson M, Enerbäck C, Rosdahl I and Söderkvist P:
Inflammasome polymorphisms confer susceptibility to sporadic
malignant melanoma. Pigment Cell Melanoma Res. 25:506–513. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Da Silva WC, Oshiro TM, de Sá DC, Franco
DD, Festa Neto C and Pontillo A: Genotyping and differential
expression analysis of inflammasome genes in sporadic malignant
melanoma reveal novel contribution of CARD8, IL1B and IL18 in
melanoma susceptibility and progression. Cancer Genet. 209:474–480.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Okamoto M, Liu W, Luo Y, Tanaka A, Cai X,
Norris DA, Dinarello CA and Fujita M: Constitutively active
inflammasome in human melanoma cells mediating autoinflammation via
caspase-1 processing and secretion of interleukin-1β. J Biol Chem.
285:6477–6488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu W, Luo Y, Dunn JH, Norris DA,
Dinarello CA and Fujita M: Dual role of apoptosis-associated
speck-like protein containing a CARD (ASC) in tumorigenesis of
human melanoma. J Invest Dermatol. 133:518–527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Drexler SK, Bonsignore L, Masin M,
Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp
J and Yazdi AS: Tissue-specific opposing functions of the
inflammasome adaptor ASC in the regulation of epithelial skin
carcinogenesis. Proc Natl Acad Sci USA. 109:18384–18389. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gonda TA, Tu S and Wang TC: Chronic
inflammation, the tumor microenvironment and carcinogenesis. Cell
Cycle. 8:2005–2013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Neagu M, Constantin C and Tanase C:
Immune-related biomarkers for diagnosis/prognosis and therapy
monitoring of cutaneous melanoma. Expert Rev Mol Diagn. 10:897–919.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nedoszytko B, Sokołowska-Wojdyło M,
Ruckemann- Dziurdzińska K, Roszkiewicz J and Nowicki RJ: Chemokines
and cytokines network in the pathogenesis of the inflammatory skin
diseases: Atopic dermatitis, psoriasis and skin mastocytosis.
Postepy Dermatol Alergol. 31:84–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Justus CR, Leffler N, Ruiz-Echevarria M
and Yang LV: In vitro cell migration and invasion assays. J Vis
Exp. 1:882014.
|
|
35
|
Kong D, Li Y, Wang Z and Sarkar FH: Cancer
stem cells and epithelial-to-mesenchymal transition
(EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel).
3:716–729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Plikus MV, Guerrero-Juarez CF, Treffeisen
E and Gay DL: Epigenetic control of skin and hair regeneration
after wounding. Exp Dermatol. 24:167–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yan C, Grimm WA, Garner WL, Qin L, Travis
T, Tan N and Han YP: Epithelial to mesenchymal transition in human
skin wound healing is induced by tumor necrosis factor-α through
bone morphogenic protein-2. Am J Pathol. 176:2247–2258. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leopold PL, Vincent J and Wang H: A
comparison of epithelial-to-mesenchymal transition and
re-epithelialization. Semin Cancer Biol. 22:471–483. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Egeblad M, Nakasone ES and Werb Z: Tumors
as organs: Complex tissues that interface with the entire organism.
Dev Cell. 18:884–901. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim Y and He YY: Ultraviolet
radiation-induced non-melanoma skin cancer: Regulation of DNA
damage repair and inflammation. Genes Dis. 1:188–198. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pondicherry A, Martin R, Meredith I, Rolfe
J, Emanuel P and Elwood M: The burden of non-melanoma skin cancers
in Auckland, New Zealand. Australas J Dermatol. 59:210–213. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Avrămoiu I, Petrescu IO, Ciurea ME, Bold
A, Siloşi I, ŢânŢu MM, Niculescu M, Anghel Savciu RE and Mogoantă
SŞ: Peritumoral inflammatory reaction in non-melanoma skin
cancers-histological and immunohistochemical study. Rom J Morphol
Embryol. 57:943–950. 2016.PubMed/NCBI
|
|
43
|
Nguyen AH, Detty SQ and Agrawal DK:
Clinical implications of high-mobility group box-1 (HMGB1) and the
receptor for advanced glycation end-products (RAGE) in cutaneous
malignancy: A systematic review. Anticancer Res. 37:1–7. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu NL and Liu FT: The expression and
function of galectins in skin physiology and pathology. Exp
Dermatol. 27:217–226. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kapucuoglu N, Basak PY, Bircan S, Sert S
and Akkaya VB: Immunohistochemical galectin-3 expression in
non-melanoma skin cancers. Pathol Res Pract. 205:97–103. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nardinocchi L, Sonego G, Passarelli F,
Avitabile S, Scarponi C, Failla CM, Simoni S, Albanesi C and Cavani
A: Interleukin-17 and interleukin-22 promote tumor progression in
human nonmelanoma skin cancer. Eur J Immunol. 45:922–931. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Von Schuckmann LA, Law MH, Montgomery GW,
Green AC and Van Der Pols JC: Vitamin D pathway gene polymorphisms
and keratinocyte cancers: A nested case-control study and
meta-analysis. Anticancer Res. 36:2145–2152. 2016.PubMed/NCBI
|
|
48
|
Dusingize JC, Olsen CM, Pandeya NP,
Subramaniam P, Thompson BS, Neale RE, Green AC and Whiteman DC;
QSkin Study, : Cigarette smoking and the risks of basal cell
carcinoma and squamous cell carcinoma. J Invest Dermatol.
137:1700–1708. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chaudhary SC, Waseem M, Rana M, Xu H,
Kopelovich L, Elmets CA and Athar M: Naproxen inhibits UVB-induced
basal cell and squamous cell carcinoma development in
Ptch1+/−/SKH-1 hairless mice. Photochem Photobiol.
93:1016–1024. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Janda J, Burkett NB, Blohm-Mangone K,
Huang V, Curiel-Lewandrowski C, Alberts DS, Petricoin EF III,
Calvert VS, Einspahr J, Dong Z, et al: Resatorvid-based
pharmacological antagonism of cutaneous TLR4 blocks UV-induced
NF-κB and AP-1 signaling in keratinocytes and mouse skin. Photochem
Photobiol. 92:816–825. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Matei C, Tampa M, Caruntu C, Ion RM,
Georgescu SR, Dumitrascu GR, Constantin C and Neagu M: Protein
microarray for complex apoptosis monitoring of dysplastic oral
keratinocytes in experimental photodynamic therapy. Biol Res.
47:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Voiculescu V, Calenic B, Ghita M, Lupu M,
Caruntu A, Moraru L, Voiculescu S, Ion A, Greabu M, Ishkitiev N, et
al: From normal skin to squamous cell carcinoma: A quest for novel
biomarkers. Dis Markers. 2016:45174922016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Voiculescu VM, Caruntu C, Solomon I, Lupu
M, Ilie MA, Boda D, Constantin C and Neagu M: Squamous cell
carcinoma: Biomarkers and potential therapeutic targets. Human Skin
Cancers - Pathways, Mechanisms, Targets and Treatments. Blumenberg
M: IntechOpen; London: pp. 135–159. 2018
|
|
54
|
Paulitschke V, Gerner C, Hofstätter E,
Mohr T, Mayer RL, Pehamberger H and Kunstfeld R: Proteome profiling
of keratinocytes transforming to malignancy. Electrophoresis.
36:564–576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Farshchian M, Nissinen L, Siljamäki E,
Riihilä P, Piipponen M, Kivisaari A, Kallajoki M, Grénman R,
Peltonen J, Peltonen S, et al: Tumor cell-specific AIM2 regulates
growth and invasion of cutaneous squamous cell carcinoma.
Oncotarget. 8:45825–45836. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Muller HK and Woods GM: Ultraviolet
radiation effects on the proteome of skin cells. Adv Exp Med Biol.
990:111–119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
López-Camarillo C, Ocampo EA, Casamichana
ML, Pérez-Plasencia C, Alvarez-Sánchez E and Marchat LA: Protein
kinases and transcription factors activation in response to
UV-radiation of skin: Implications for carcinogenesis. Int J Mol
Sci. 13:142–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Bertrand-Vallery V, Boilan E, Ninane N,
Demazy C, Friguet B, Toussaint O, Poumay Y and Debacq-Chainiaux F:
Repeated exposures to UVB induce differentiation rather than
senescence of human keratinocytes lacking p16(INK-4A).
Biogerontology. 11:167–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Föll MC, Fahrner M, Gretzmeier C, Thoma K,
Biniossek ML, Kiritsi D, Meiss F, Schilling O, Nyström A and Kern
JS: Identification of tissue damage, extracellular matrix
remodeling and bacterial challenge as common mechanisms associated
with high-risk cutaneous squamous cell carcinomas. Matrix Biol.
66:1–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Guerra L, Odorisio T, Zambruno G and
Castiglia D: Stromal microenvironment in type VII
collagen-deficient skin: The ground for squamous cell carcinoma
development. Matrix Biol. 63:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Meier K, Drexler SK, Eberle FC, Lefort K
and Yazdi AS: Silencing of ASC in cutaneous squamous cell
carcinoma. PLoS One. 11:e01647422016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kirkley KS, Walton KD, Duncan C and
Tjalkens RB: Spontaneous development of cutaneous squamous cell
carcinoma in mice with cell-specific deletion of inhibitor of κB
kinase 2. Comp Med. 67:407–415. 2017.PubMed/NCBI
|
|
63
|
Mohanan S, Horibata S, Anguish LJ, Mukai
C, Sams K, McElwee JL, McLean D, Yan A and Coonrod SA: PAD2
overexpression in transgenic mice augments malignancy and
tumor-associated inflammation in chemically initiated skin tumors.
Cell Tissue Res. 370:275–283. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Atmatzidis DH, Lambert WC and Lambert MW:
Langerhans cell: Exciting developments in health and disease. J Eur
Acad Dermatol Venereol. 31:1817–1824. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lin M, Sutherland DR, Horsfall W, Totty N,
Yeo E, Nayar R, Wu XF and Schuh AC: Cell surface antigen CD109 is a
novel member of the α(2) macroglobulin/C3, C4, C5 family of
thioester-containing proteins. Blood. 99:1683–1691. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sunagawa M, Mii S, Enomoto A, Kato T,
Murakumo Y, Shiraki Y, Asai N, Asai M, Nagino M and Takahashi M:
Suppression of skin tumorigenesis in CD109-deficient mice.
Oncotarget. 7:82836–82850. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Varricchi G, Galdiero MR and Marone G,
Granata F, Borriello F and Marone G: Controversial role of mast
cells in skin cancers. Exp Dermatol. 26:11–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Latil M, Nassar D, Beck B, Boumahdi S,
Wang L, Brisebarre A, Dubois C, Nkusi E, Lenglez S, Checinska A, et
al: Cell-type-specific chromatin states differentially prime
squamous cell carcinoma tumor-initiating cells for epithelial to
mesenchymal transition. Cell Stem Cell. 20:191–204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dibra D, Mitra A, Newman M, Xia X, Keenan
C, Cutrera JJ, Mathis JM, Wang XJ, Myers J and Li S: IL27 controls
skin tumorigenesis via accumulation of ETAR-positive CD11b cells in
the pre-malignant skin. Oncotarget. 7:77138–77151. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ghita MA, Caruntu C, Rosca AE, Kaleshi H,
Caruntu A, Moraru L, Docea AO, Zurac S, Boda D, Neagu M, et al:
Reflectance confocal microscopy and dermoscopy for in vivo,
non-invasive skin imaging of superficial basal cell carcinoma.
Oncol Lett. 11:3019–3024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tilley C, Deep G and Agarwal R:
Chemopreventive opportunities to control basal cell carcinoma:
Current perspectives. Mol Carcinog. 54:688–697. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jia J, Shi Y, Yan B, Xiao D, Lai W, Pan Y,
Jiang Y, Chen L, Mao C, Zhou J, et al: LGR5 expression is controled
by IKKα in basal cell carcinoma through activating STAT3 signaling
pathway. Oncotarget. 7:27280–27294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Larsimont JC, Youssef KK, Sánchez-Danés A,
Sukumaran V, Defrance M, Delatte B, Liagre M, Baatsen P, Marine JC,
Lippens S, et al: Sox9 controls self-renewal of oncogene targeted
cells and links tumor initiation and invasion. Cell Stem Cell.
17:60–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chastkofsky MI, Bie W, Ball-Kell SM, He YY
and Tyner AL: Protein tyrosine kinase 6 regulates UVB-induced
signaling and tumorigenesis in mouse skin. J Invest Dermatol.
135:2492–2501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Baykan H, Cihan YB and Ozyurt K: Roles of
white blood cells and subtypes as inflammatory markers in skin
cancer. Asian Pac J Cancer Prev. 16:2303–2306. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe
LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki
M, et al: Neuroendocrine factors: The missing link in non melanoma
skin cancer (Review). Oncol Rep. 38:1327–1340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Lin Y, Chahal HS, Wu W, Cho HG, Ransohoff
KJ, Dai H, Tang JY, Sarin KY and Han J: Association between genetic
variation within vitamin D receptor-DNA binding sites and risk of
basal cell carcinoma. Int J Cancer. 140:2085–2091. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Κaukinen A, Siiskonen H, Pelkonen J and
Harvima IT: Immunoreactivity to CYP24A1, but not vitamin D
receptor, is increased in mast cells of keratinocyte skin cancers.
Eur J Dermatol. 27:590–598. 2017.PubMed/NCBI
|
|
79
|
Weidenbusch M, Rodler S, Song S, Romoli S,
Marschner JA, Kraft F, Holderied A, Kumar S, Mulay SR, Honarpisheh
M, et al: Gene expression profiling of the Notch-AhR-IL22 axis at
homeostasis and in response to tissue injury. Biosci Rep.
37:BSR201700992017.doi: 10.1042/BSR20170099. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Rubina KA, Sysoeva VY, Zagorujko EI,
Tsokolaeva ZI, Kurdina MI, Parfyonova YV and Tkachuk VA: Increased
expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal
cell carcinomas. Arch Dermatol Res. 309:433–442. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kuznetsova EV, Snarskaya ES, Zavalishina
LE and Tkachenko SB: Immunohistochemical study of the specific
features of expression of matrix metalloproteinases 1, 9 in the
photoaged skin, the foci of actinic keratosis and basal cell
carcinoma. Arkh Patol. 78:17–22. 2016.(In Russian). View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Papakostas D and Stockfleth E: Topical
treatment of basal cell carcinoma with the immune response modifier
imiquimod. Future Oncol. 11:2985–2990. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Muranushi C, Olsen CM, Green AC and
Pandeya N: Can oral nonsteroidal antiinflammatory drugs play a role
in the prevention of basal cell carcinoma? A systematic review and
metaanalysis. J Am Acad Dermatol. 74:108–119.e1. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Barnes TA and Amir E: HYPE or HOPE: The
prognostic value of infiltrating immune cells in cancer. Br J
Cancer. 117:451–460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Weiss SA, Han SW, Lui K, Tchack J, Shapiro
R, Berman R, Zhong J, Krogsgaard M, Osman I and Darvishian F:
Immunologic heterogeneity of tumor-infiltrating lymphocyte
composition in primary melanoma. Hum Pathol. 57:116–125. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zurac S, Negroiu G, Andrei R, Petrescu S,
Tebeica T, Petre M, Neagu M, Constantin C, Chitu V, Salavastru C,
et al: Inflammatory infiltrate in melanoma with regression as
prognostic parameter. Virchows Arch. 463:1272013.
|
|
87
|
Klechevsky E: Functional diversity of
human dendritic cells. Adv Exp Med Biol. 850:43–54. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hargadon KM: Strategies to improve the
efficacy of dendritic cell-based immunotherapy for melanoma. Front
Immunol. 8:15942017. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Van de Ven R, van den Hout MF, Lindenberg
JJ, Sluijter BJ, Van Leeuwen PA, Lougheed SM, Meijer S, Van den Tol
MP, Scheper RJ and De Gruijl TD: Characterization of four
conventional dendritic cell subsets in human skin-draining lymph
nodes in relation to T-cell activation. Blood. 118:2502–2510. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Deckers J, Hammad H and Hoste E:
Langerhans cells: Sensing the environment in health and disease.
Front Immunol. 9:932018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Klechevsky E, Morita R, Liu M, Cao Y,
Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G,
Palucka AK, et al: Functional specializations of human epidermal
Langerhans cells and CD14+ dermal dendritic cells.
Immunity. 29:497–510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Price JG, Idoyaga J, Salmon H, Hogstad B,
Bigarella CL, Ghaffari S, Leboeuf M and Merad M: CDKN1A regulates
Langerhans cell survival and promotes Treg cell generation upon
exposure to ionizing irradiation. Nat Immunol. 16:1060–1068. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Hieronymus T, Zenke M, Baek JH and Seré K:
The clash of Langerhans cell homeostasis in skin: Should I stay or
should I go? Semin Cell Dev Biol. 41:30–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Yasmin N, Bauer T, Modak M, Wagner K,
Schuster C, Köffel R, Seyerl M, Stöckl J, Elbe-Bürger A, Graf D, et
al: Identification of bone morphogenetic protein 7 (BMP7) as an
instructive factor for human epidermal Langerhans cell
differentiation. J Exp Med. 210:2597–2610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Arwert EN, Hoste E and Watt FM: Epithelial
stem cells, wound healing and cancer. Nat Rev Cancer. 12:170–180.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Baek JH, Birchmeier C, Zenke M and
Hieronymus T: The HGF receptor/Met tyrosine kinase is a key
regulator of dendritic cell migration in skin immunity. J Immunol.
189:1699–1707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yen JH, Khayrullina T and Ganea D:
PGE2-induced metalloproteinase-9 is essential for dendritic cell
migration. Blood. 111:260–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Haanen JB, Baars A, Gomez R, Weder P,
Smits M, De Gruijl TD, Von Blomberg BM, Bloemena E, Scheper RJ, Van
Ham SM, et al: Melanoma-specific tumor-infiltrating lymphocytes but
not circulating melanoma-specific T cells may predict survival in
resected advanced-stage melanoma patients. Cancer Immunol
Immunother. 55:451–458. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ladányi A, Kiss J, Somlai B, Gilde K,
Fejos Z, Mohos A, Gaudi I and Tímár J: Density of
DC-LAMP+ mature dendritic cells in combination with
activated T lymphocytes infiltrating primary cutaneous melanoma is
a strong independent prognostic factor. Cancer Immunol Immunother.
56:1459–1469. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Dai J, El Gazzar M, Li GY, Moorman JP and
Yao ZQ: Myeloid-derived suppressor cells: Paradoxical roles in
infection and immunity. J Innate Immun. 7:116–126. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Mao Y, Poschke I, Wennerberg E, Pico de
Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G,
Lundqvist A and Kiessling R: Melanoma-educated CD14+
cells acquire a myeloid-derived suppressor cell phenotype through
COX-2-dependent mechanisms. Cancer Res. 73:3877–3887. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bronte V, Brandau S, Chen SH, Colombo MP,
Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A,
Ostrand-Rosenberg S, et al: Recommendations for myeloid-derived
suppressor cell nomenclature and characterization standards. Nat
Commun. 7:121502016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Tarhini AA, Edington H, Butterfield LH,
Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, et
al: Immune monitoring of the circulation and the tumor
microenvironment in patients with regionally advanced melanoma
receiving neoadjuvant ipilimumab. PLoS One. 9:e877052014.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Rudolph BM, Loquai C, Gerwe A, Bacher N,
Steinbrink K, Grabbe S and Tuettenberg A: Increased frequencies of
CD11b+ CD33+ CD14+
HLA-DRlow myeloid-derived suppressor cells are an early
event in melanoma patients. Exp Dermatol. 23:202–204. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Martens A, Zelba H, Garbe C, Pawelec G and
Weide B: Monocytic myeloid-derived suppressor cells in advanced
melanoma patients: Indirect impact on prognosis through inhibition
of tumor-specific T-cell responses? OncoImmunology. 3:e278452014.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Filipazzi P, Pilla L, Mariani L, Patuzzo
R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G,
Giardino F, et al: Limited induction of tumor cross-reactive T
cells without a measurable clinical benefit in early melanoma
patients vaccinated with human leukocyte antigen class I-modified
peptides. Clin Cancer Res. 18:6485–6496. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Brandau S, Trellakis S, Bruderek K,
Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J,
Zabel P, et al: Myeloid-derived suppressor cells in the peripheral
blood of cancer patients contain a subset of immature neutrophils
with impaired migratory properties. J Leukoc Biol. 89:311–317.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Schilling B, Sucker A, Griewank K, Zhao F,
Weide B, Görgens A, Giebel B, Schadendorf D and Paschen A:
Vemurafenib reverses immunosuppression by myeloid derived
suppressor cells. Int J Cancer. 133:1653–1663. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ene CD, Anghel AE, Neagu M and Nicolae I:
25-OH Vitamin D and interleukin-8 emerging biomarkers in cutaneous
melanoma development and progression. Mediators Inflam. 2015:1–8.
2015. View Article : Google Scholar
|
|
110
|
Mandruzzato S, Solito S, Falisi E,
Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR,
Nitti D, Bronte V, et al: IL4Rα+ myeloid-derived
suppressor cell expansion in cancer patients. J Immunol.
182:6562–6568. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Jiang H, Gebhardt C, Umansky L, Beckhove
P, Schulze TJ, Utikal J and Umansky V: Elevated chronic
inflammatory factors and myeloid-derived suppressor cells indicate
poor prognosis in advanced melanoma patients. Int J Cancer.
136:2352–2360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhai Z, Liu W, Kaur M, Luo Y, Domenico J,
Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA, et al:
NLRP1 promotes tumor growth by enhancing inflammasome activation
and suppressing apoptosis in metastatic melanoma. Oncogene.
36:3820–3830. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Lopes RL, Borges TJ, Araújo JF, Pinho NG,
Bergamin LS, Battastini AM, Muraro SP, Souza AP, Zanin RF and
Bonorino C: Extracellular mycobacterial DnaK polarizes macrophages
to the M2-like phenotype. PLoS One. 9:e1134412014. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Scali E, Mignogna C, Di Vito A, Presta I,
Camastra C, Donato G and Bottoni U: Inflammation and macrophage
polarization in cutaneous melanoma: Histopathological and
immunohistochemical study. Int J Immunopathol Pharmacol.
29:715–719. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Falleni M, Savi F, Tosi D, Agape E, Cerri
A, Moneghini L and Bulfamante GP: M1 and M2 macrophages'
clinicopathological significance in cutaneous melanoma. Melanoma
Res. 27:200–210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Bønnelykke-Behrndtz ML, Steiniche T,
Damsgaard TE, Georgsen JB, Danielsen A, Bastholt L, Møller HJ,
Nørgaard PH and Schmidt H: MelanA-negative spindle-cell associated
melanoma, a distinct inflammatory phenotype correlated with dense
infiltration of CD163 macrophages and loss of E-cadherin. Melanoma
Res. 25:113–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Jacquelot N, Pitt JM, Enot DP, Roberti MP,
Duong CPM, Rusakiewicz S, Eggermont AM and Zitvogel L: Immune
biomarkers for prognosis and prediction of responses to immune
checkpoint blockade in cutaneous melanoma. OncoImmunology.
6:e12993032017. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Hernberg M, Mattila PS, Rissanen M,
Hansson J, Aamdal S, Bastholt L, Von der Maase H, Schmidt H,
Stierner U and Tarkkanen J: The prognostic role of blood lymphocyte
subset distribution in patients with resected high-risk primary or
regionally metastatic melanoma. J Immunother. 30:773–779. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Fridman WH, Galon J, Pagès F, Tartour E,
Sautès-Fridman C and Kroemer G: Prognostic and predictive impact of
intra- and peritumoral immune infiltrates. Cancer Res.
71:5601–5605. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Jacobs JFM, Nierkens S, Figdor CG, de
Vries IJM and Adema GJ: Regulatory T cells in melanoma: The final
hurdle towards effective immunotherapy? Lancet Oncol. 13:e32–e42.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Nevala WK, Vachon CM, Leontovich AA, Scott
CG, Thompson MA and Markovic SN: Melanoma study group of the Mayo
Clinic Cancer Center: Evidence of systemic Th2-driven chronic
inflammation in patients with metastatic melanoma. Clin Cancer Res.
15:1931–1939. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Umansky V and Sevko A: Melanoma-induced
immunosuppression and its neutralization. Semin Cancer Biol.
22:319–326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Burkholder B, Huang RY, Burgess R, Luo S,
Jones VS, Zhang W, Lv ZQ, Gao CY, Wang BL, Zhang YM, et al:
Tumor-induced perturbations of cytokines and immune cell networks.
Biochim Biophys Acta. 1845:182–201. 2014.PubMed/NCBI
|
|
124
|
Neagu M, Constantin C and Longo C:
Chemokines in the melanoma metastasis biomarkers portrait. J
Immunoassay Immunochem. 36:559–566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wang W, Edington HD, Rao UN, Jukic DM,
Radfar A, Wang H and Kirkwood JM: Effects of high-dose IFNα2b on
regional lymph node metastases of human melanoma: Modulation of
STAT5, FOXP3, and IL-17. Clin Cancer Res. 14:8314–8320. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Neagu M, Constantin C and Zurac S: Immune
parameters in the prognosis and therapy monitoring of cutaneous
melanoma patients: Experience, role, and limitations. BioMed Res
Int. 2013:1079402013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Nguyen LT, Yen PH, Nie J, Liadis N,
Ghazarian D, Al-Habeeb A, Easson A, Leong W, Lipa J, McCready D, et
al: Expansion and characterization of human melanoma
tumor-infiltrating lymphocytes (TILs). PLoS One. 5:e139402010.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ηussein MR, Elsers DA, Fadel SA and Omar
AE: Immunohistological characterisation of tumour infiltrating
lymphocytes in melanocytic skin lesions. J Clin Pathol. 59:316–324.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Azimi F, Scolyer RA, Rumcheva P, Moncrieff
M, Murali R, McCarthy SW, Saw RP and Thompson JF:
Tumor-infiltrating lymphocyte grade is an independent predictor of
sentinel lymph node status and survival in patients with cutaneous
melanoma. J Clin Oncol. 30:2678–2683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Burton AL, Roach BA, Mays MP, Chen AF,
Ginter BA, Vierling AM, Scoggins CR, Martin RC, Stromberg AJ,
Hagendoorn L, et al: Prognostic significance of tumor infiltrating
lymphocytes in melanoma. Am Surg. 77:188–192. 2011.PubMed/NCBI
|
|
131
|
Kluger HM, Zito CR, Barr ML, Baine MK,
Chiang VL, Sznol M, Rimm DL, Chen L and Jilaveanu LB:
Characterization of PD-L1 expression and associated T-cell
infiltrates in metastatic melanoma samples from variable anatomic
sites. Clin Cancer Res. 21:3052–3060. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Ancuceanu R and Neagu M: Immune based
therapy for melanoma. Indian J Med Res. 143:135–144. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Ménard C, Ghiringhelli F, Roux S, Chaput
N, Mateus C, Grohmann U, Caillat-Zucman S, Zitvogel L and Robert C:
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells
in advanced melanoma: Surrogate marker of efficacy of tremelimumab?
Clin Cancer Res. 14:5242–5249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sarff M, Edwards D, Dhungel B, Wegmann KW,
Corless C, Weinberg AD and Vetto JT: OX40 (CD134) expression in
sentinel lymph nodes correlates with prognostic features of primary
melanomas. Am J Surg. 195:621–625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Garg K, Maurer M, Griss J, Brüggen MC,
Wolf IH, Wagner C, Willi N, Mertz KD and Wagner SN:
Tumor-associated B cells in cutaneous primary melanoma and improved
clinical outcome. Hum Pathol. 54:157–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Chiou SH, Sheu BC, Chang WC, Huang SC and
Hong-Nerng H: Current concepts of tumor-infiltrating lymphocytes in
human malignancies. J Reprod Immunol. 67:35–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Staquicini FI, Tandle A, Libutti SK, Sun
J, Zigler M, Bar-Eli M, Aliperti F, Pérez EC, Gershenwald JE,
Mariano M, et al: A subset of host B-lymphocytes control melanoma
metastasis through a MCAM/MUC18-dependent interaction: Evidence
from mice and humans. Cancer Res. 68:8419–8428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sadozai H, Gruber T, Hunger RE and Schenk
M: Recent successes and future directions in immunotherapy of
cutaneous melanoma. Front Immunol. 8:16172017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Tarazona R, Duran E and Solana R: Natural
killer cell recognition of melanoma: New clues for a more effective
immunotherapy. Front Immunol. 6:6492016. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ballas ZK, Buchta CM, Rosean TR, Heusel JW
and Shey MR: Role of NK cell subsets in organ-specific murine
melanoma metastasis. PLoS One. 8:e655992013. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ali TH, Pisanti S, Ciaglia E, Mortarini R,
Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto
C, et al: Enrichment of
CD56dimKIR+CD57+ highly cytotoxic
NK cells in tumour-infiltrated lymph nodes of melanoma patients.
Nat Commun. 5:56392014. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Nielsen N, Ødum N, Ursø B, Lanier LL and
Spee P: Cytotoxicity of CD56bright NK cells towards
autologous activated CD4+ T cells is mediated through
NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS One.
7:e319592012. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Morvan MG and Lanier LL: NK cells and
cancer: You can teach innate cells new tricks. Nat Rev Cancer.
16:7–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Mendez R, Aptsiauri N, Del Campo A, Maleno
I, Cabrera T, Ruiz-Cabello F, Garrido F and Garcia-Lora A: HLA and
melanoma: Multiple alterations in HLA class I and II expression in
human melanoma cell lines from ESTDAB cell bank. Cancer Immunol
Immunother. 58:1507–1515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Baumeister SH, Freeman GJ, Dranoff G and
Sharpe AH: Coinhibitory pathways in immunotherapy for cancer. Annu
Rev Immunol. 34:539–573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Terme M, Ullrich E, Aymeric L, Meinhardt
K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G,
et al: IL-18 induces PD-1-dependent immunosuppression in cancer.
Cancer Res. 71:5393–5399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Singh S, Singh AP, Sharma B, Owen LB and
Singh RK: CXCL8 and its cognate receptors in melanoma progression
and metastasis. Future Oncol. 6:111–116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Gras Navarro A, Bjorklund AT and Chekenya
M: Therapeutic potential and challenges of natural killer cells in
treatment of solid tumors. Front Immunol. 6:2022015. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Rosenberg J and Huang J: CD8+ T
cells and NK cells: Parallel and complementary soldiers of
immunotherapy. Curr Opin Chem Eng. 19:9–20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
De Lecea MV, Palomares T, Al Kassam D,
Cavia M, Geh JLC, De Llano P, Muñiz P, Armesto D, Martinez-Indart L
and Alonso-Varona A: Indoleamine 2,3 dioxygenase as a prognostic
and follow-up marker in melanoma. A comparative study with LDH and
S100B. J Eur Acad Dermatol Venereol. 31:636–642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Tarhini AA, Lin Y, Yeku O, LaFramboise WA,
Ashraf M, Sander C, Lee S and Kirkwood JM: A four-marker signature
of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival
in high-risk surgically resected melanoma. J Transl Med. 12:192014.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Zurac S, Neagu M, Constantin C, Cioplea M,
Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et
al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in
cutaneous melanoma with regression and their possible function as
prognostic predictors. Oncol Lett. 11:3354–3360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Hofmann MA, Kiecker F, Küchler I, Kors C
and Trefzer U: Serum TNF-α, B2M and sIL-2R levels are biological
correlates of outcome in adjuvant IFN-α2b treatment of patients
with melanoma. J Cancer Res Clin Oncol. 137:455–462. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Porter GA, Abdalla J, Lu M, Smith S,
Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE and
Lee JE: Significance of plasma cytokine levels in melanoma patients
with histologically negative sentinel lymph nodes. Ann Surg Oncol.
8:116–122. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Hu X, Li B, Li X, Zhao X, Wan L, Lin G, Yu
M, Wang J, Jiang X, Feng W, et al: Transmembrane TNF-α promotes
suppressive activities of myeloid-derived suppressor cells via
TNFR2. J Immunol. 192:1320–1331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Polz J, Remke A, Weber S, Schmidt D,
Weber-Steffens D, Pietryga-Krieger A, Müller N, Ritter U, Mostböck
S and Männel DN: Myeloid suppressor cells require membrane TNFR2
expression for suppressive activity. Immun Inflamm Dis. 2:121–130.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Chen X and Oppenheim JJ: TNF-α: An
activator of CD4+FoxP3+TNFR2+
regulatory T cells. Curr Dir Autoimmun. 11:119–134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Balch CM, Buzaid AC, Soong SJ, Atkins MB,
Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr,
Kirkwood JM, et al: Final version of the American Joint Committee
on cancer staging system for cutaneous melanoma. J Clin Oncol.
19:3635–3648. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Gershenwald JE, Scolyer RA, Hess KR,
Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM,
McArthur GA, et al: Melanoma staging: Evidence-based changes in the
American Joint Committee on cancer eighth edition cancer staging
manual. CA Cancer J Clin. 67:472–492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Weide B, Richter S, Büttner P, Leiter U,
Forschner A, Bauer J, Held L, Eigentler TK, Meier F and Garbe C:
Serum S100B, lactate dehydrogenase and brain metastasis are
prognostic factors in patients with distant melanoma metastasis and
systemic therapy. PLoS One. 8:e816242013. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Karonidis A, Mantzourani M, Gogas H and
Tsoutsos D: Serum S100B levels correlate with stage, N status,
mitotic rate and disease outcome in melanoma patients independent
to LDH. J BUON. 22:1296–1302. 2017.PubMed/NCBI
|
|
162
|
Von Bauer R, Oikonomou D, Sulaj A,
Mohammed S, Hotz-Wagenblatt A, Gröne HJ, Arnold B, Falk C, Luethje
D, Erhardt A, et al: CD166/ALCAM mediates proinflammatory effects
of S100B in delayed type hypersensitivity. J Immunol. 191:369–377.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Dumitraşcu G, Constantin C, Manda G,
Hristescu S, Mărgaritescu I, Chiriţă D and Neagu M: Serum markers
in skin melanoma-preliminary study. Roum Arch Microbiol Immunol.
68:125–135. 2009.PubMed/NCBI
|
|
164
|
Schmidt J, Riechers A, Stoll R, Amann T,
Fink F, Spruss T, Gronwald W, König B, Hellerbrand C and Bosserhoff
AK: Targeting melanoma metastasis and immunosuppression with a new
mode of melanoma inhibitory activity (MIA) protein inhibition. PLoS
One. 7:e379412012. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Findeisen P, Zapatka M, Peccerella T,
Matzk H, Neumaier M, Schadendorf D and Ugurel S: Serum amyloid A as
a prognostic marker in melanoma identified by proteomic profiling.
J Clin Oncol. 27:2199–2208. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Neagu M and Constantin C: Immune-therapy
in cutaneous melanoma-efficacy immune markers. Advancements in
Tumor Immunotherapy and Cancer Vaccines. Arnouk H: InTech; Rijeka,
Croatia: pp. 83–106. 2012
|
